This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor



Published: May 15, 2013


In the Academic Highlights section "Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management" by John Zajecka, MD, and colleagues in the April 2013 issue (J Clin Psychiatry 2013;74[4]:407-414), Lundbeck should have been listed as a joint supporter. The corrected statement on page 407 (lower left column) is as follows:

  • Financial support for preparation and dissemination of this Academic Highlights was provided by Takeda Pharmaceuticals U.S.A., Inc., and Lundbeck.

The online version is correct.

Volume: 74

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...